Links to articles in the current and previous 2 issues of this bulletin are displayed below.
To receive email notifications about new issues of this bulletin, please email: richard.fallis@healthcarelibrary.qub.ac.uk
Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia 10.1016/j.blre.2024.101208
Blood and guts: how the intestinal microbiome shapes hematopoiesis and treatment of hematologic disease 10.1182/blood.2023021174
Bone marrow niches for hematopoietic stem cells: life span dynamics and adaptation to acute stress 10.1182/blood.2023023788
Current status and prospect of anti-amyloid fibril therapy in AL amyloidosis 10.1016/j.blre.2024.101207
DNA damage response defects in hematologic malignancies: mechanistic insights and therapeutic strategies 10.1182/blood.2023019963
Early palliative care in haematological malignancies 10.1136/spcare-2024-004812
Escape from T-cell–targeting immunotherapies in acute myeloid leukemia 10.1182/blood.2023019961
Effectiveness of ferritin-guided donation intervals in whole-blood donors in the Netherlands (FIND'EM): a stepped-wedge cluster-randomised trial 10.1016/S0140-6736(24)01085-7
Evidence for antigen presentation by human neutrophils 10.1182/blood.2023023444
Heparan sulfates and heparan sulfate proteoglycans in hematopoiesis 10.1182/blood.2023022736
How I treat long-term survivors of childhood acute leukemia 10.1182/blood.2023019804
How I treat the co-occurrence of venous and arterial thromboembolism: anticoagulation, antiplatelet therapy, or both? 10.1182/blood.2023021638
How I use genomics and BTK inhibitors in the treatment of Waldenström macroglobulinemia 10.1182/blood.2022017235
Ivosidenib with azacitidine for untreated acute myeloid leukaemia with an IDH1 R132 mutation (new NICE guideline TA979)
Malignant progression of preleukemic disorders 10.1182/blood.2023020817
Short-term and long-term survival in patients with prevalent haemodialysis—an integrated prognostic model: external validation 10.1136/spcare-2022-003916
Tricking the trickster: precision medicine approaches to counteract leukemia immune escape after transplant 10.1182/blood.2023019962
Voxelotor for treating haemolytic anaemia caused by sickle cell disease (new NICE guideline TA981)
What clinicians should know about surrogate end points in hematologic malignancies 10.1182/blood.2023022269
Blood (25th Apr-4th Jul); Blood Reviews (Jul); BMJ Supportive and Palliative Care (Jun); Lancet, The (Jul); NICE website (Jun)
Arteriovenous access for hemodialysis: a review 10.1001/jama.2024.0535
BCMA- or GPRC5D-targeting bispecific antibodies in multiple myeloma: efficacy, safety, and resistance mechanisms 10.1182/blood.2023022499
Biology of factor XI (review) 10.1182/blood.2023020719
Cell cross talk within the lymphoma tumor microenvironment: follicular lymphoma as a paradigm 10.1182/blood.2023021000
Consensus recommendations on the management of toxicity associated with CD3×CD20 bispecific antibody therapy 10.1182/blood.2023022432
Degraders upgraded: the rise of PROTACs in hematological malignancies 10.1182/blood.2023022993
The essential microenvironmental role of oligomannoses specifically inserted into the antigen-binding sites of lymphoma cells 10.1182/blood.2023022703
Factor XI deficiency: phenotypic age-related considerations and clinical approach towards bleeding risk assessment 10.1182/blood.2023020721
The follicular lymphoma tumor microenvironment at single-cell and spatial resolution 10.1182/blood.2023020999
Genetic mechanisms underlying tumor microenvironment composition and function in diffuse large B-cell lymphoma 10.1182/blood.2023021002
Home versus in‐centre haemodialysis for people with kidney failure (updated Cochrane intervention review) 10.1002/14651858.CD009535.pub3
How I manage acute respiratory failure in patients with hematological malignancies 10.1182/blood.2023021414
How I reduce and treat posttransplant relapse of MDS 10.1182/blood.2023023005
Kurin Lock for blood culture collection (new NICE guideline MTG77)
Recent developments in the use of pyruvate kinase activators as a new approach for treating sickle cell disease 10.1182/blood.2023021167
T-cell dysfunctions in myelodysplastic syndromes 10.1182/blood.2023023166
Targeting factor XI and factor XIa to prevent thrombosis 10.1182/blood.2023020722
“Treatment with curative intent”: the emergence of genetic therapies for sickle cell anemia 10.1182/blood.2023021598
Blood (Mar-18th Apr); Cochrane Library (Mar-Apr); JAMA (18th Mar); NICE website (Apr)
Access to CAR T-cell therapy: Focus on diversity, equity and inclusion 10.1016/j.blre.2023.101136
CAR T-cell therapy in multiple myeloma: mission accomplished? 10.1182/blood.2023021221
Clinical decision support to enhance venous thromboembolism pharmacoprophylaxis prescribing for pediatric inpatients with COVID-19 10.1002/pbc.30843
The current challenges faced by people with hemophilia B 10.1111/ejh.14135
Efficacy and safety of letermovir prophylaxis for cytomegalovirus infection after hematopoietic stem cell transplantation 10.1097/BS9.0000000000000178
Haematopoietic stem cell health in sickle cell disease and its implications for stem cell therapies and secondary haematological disorders 10.1016/j.blre.2023.101137
Hoping for a normal life: Decision-making on hematopoietic stem cell transplantation by patients with a hemoglobinopathy and their caregivers 10.1002/pbc.30808
The lifelong natural history of clonal hematopoiesis and its links to myeloid neoplasia 10.1182/blood.2023019964
Myeloma and DNA damage 10.1182/blood.2023021384
The influence of immunodeficiency, disease features, and patient characteristics on survival in plasmablastic lymphoma 10.1182/blood.2023021348
The many facets of immune-mediated thrombocytopenia: Principles of immunobiology and immunotherapy 10.1016/j.blre.2023.101141
Measuring neurobehavioral side effects of corticosteroids in pediatric acute lymphoblastic leukemia: A scoping review 10.1002/pbc.30881
Neonatal hemophagocytic lymphohistiocytosis: A meta-analysis of 205 cases 10.1002/pbc.30894
Non‐clotting factor therapies for preventing bleeds in people with congenital hemophilia A or B (new Cochrane intervention review) 10.1002/14651858.CD014544.pub2
A paradox of choice: Sequencing therapy in relapsed/refractory diffuse large B-cell lymphoma 10.1016/j.blre.2023.101140
Red blood cell capacity of modern menstrual products: considerations for assessing heavy menstrual bleeding 10.1136/bmjsrh-2023-201895
Social determinants of health predict health outcomes following pediatric allogeneic hematopoietic stem cell transplant 10.1002/pbc.30892
Teclistamab-cqyv in multiple myeloma 10.1111/ejh.14121
Blood (Jan-Feb); Blood Reviews (Jan); Blood Science (Jan); BMJ Sexual and Reproductive Health (Jan); Cochrane Library (Feb-Mar); European Journal of Haematology (Mar); Pediatric Blood and Cancer (Mar-Apr)